| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.093 | 0.02 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |